Story perspectives

IonQ Partners with CCRM to Revolutionize Therapeutic Development

12/2/2025

Summary

Story summary

IonQ, Inc. and the Centre for Commercialization of Regenerative Medicine (CCRM) announced in December 2025 a partnership to advance therapeutic development with hybrid quantum and quantum-AI technologies.
IonQ will be the core technology partner within CCRM’s global network, which includes over 100,000 square feet of GMP facilities and more than 300 scientists.
Initial projects will launch in Canada and Sweden in 2026, focusing on bioprocess optimization and disease modeling, leveraging IonQ’s quantum advances including 99.99% two-qubit gate fidelity in 2025.

1 of 1

Story summary

IonQ, Inc. and the Centre for Commercialization of Regenerative Medicine (CCRM) announced in December 2025 a partnership to advance therapeutic development with hybrid quantum and quantum-AI technologies.
IonQ will be the core technology partner within CCRM’s global network, which includes over 100,000 square feet of GMP facilities and more than 300 scientists.
Initial projects will launch in Canada and Sweden in 2026, focusing on bioprocess optimization and disease modeling, leveraging IonQ’s quantum advances including 99.99% two-qubit gate fidelity in 2025.